Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Operating Expenses: 2021-2025

Historic Operating Expenses for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $12.7 million.

  • SAB Biotherapeutics' Operating Expenses rose 12.11% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.3 million, marking a year-over-year decrease of 18.73%. This contributed to the annual value of $44.2 million for FY2024, which is 9.72% up from last year.
  • SAB Biotherapeutics' Operating Expenses amounted to $12.7 million in Q3 2025, which was up 30.28% from $9.7 million recorded in Q2 2025.
  • SAB Biotherapeutics' Operating Expenses' 5-year high stood at $21.1 million during Q2 2021, with a 5-year trough of $6.6 million in Q2 2023.
  • For the 3-year period, SAB Biotherapeutics' Operating Expenses averaged around $10.7 million, with its median value being $10.5 million (2024).
  • Over the last 5 years, SAB Biotherapeutics' Operating Expenses had its largest YoY gain of 91.39% in 2023, and its largest YoY loss of 56.87% in 2023.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Operating Expenses stood at $18.4 million in 2021, then slumped by 45.55% to $10.0 million in 2022, then surged by 91.39% to $19.2 million in 2023, then crashed by 47.21% to $10.1 million in 2024, then grew by 12.11% to $12.7 million in 2025.
  • Its Operating Expenses stands at $12.7 million for Q3 2025, versus $9.7 million for Q2 2025 and $10.8 million for Q1 2025.